Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation

Biallelic mutations in the SLC30A10 gene cause an inborn error of Mn metabolism characterized by hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis (HMDPC). To date, only 14 families from various ethnic groups have been reported. Here, we describe 10 patients from 7 unrelated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical genetics 2018-04, Vol.93 (4), p.905-912
Hauptverfasser: Zaki, M.S., Issa, M.Y., Elbendary, H.M., El‐Karaksy, H., Hosny, H., Ghobrial, C., El Safty, A., El‐Hennawy, A., Oraby, A., Selim, L., Abdel‐Hamid, M.S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 912
container_issue 4
container_start_page 905
container_title Clinical genetics
container_volume 93
creator Zaki, M.S.
Issa, M.Y.
Elbendary, H.M.
El‐Karaksy, H.
Hosny, H.
Ghobrial, C.
El Safty, A.
El‐Hennawy, A.
Oraby, A.
Selim, L.
Abdel‐Hamid, M.S.
description Biallelic mutations in the SLC30A10 gene cause an inborn error of Mn metabolism characterized by hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis (HMDPC). To date, only 14 families from various ethnic groups have been reported. Here, we describe 10 patients from 7 unrelated Egyptian families with HMDPC. Markedly elevated blood Mn levels, the characteristic basal ganglia hyperintensity on T1‐weighted images, and variable degrees of extrapyramidal manifestations with or without liver disease were cardinal features in all patients. Eight patients presented with striking early diseased onset (≤2 years). Unexpectedly, early hepatic involvement before the neurological regression was noted in 3 patients. Mutational analysis of SLC30A10 gene revealed 6 novel homozygous mutations (c.77T > C (p.Leu26Pro), c.90C > G (p.Tyr30*), c.119A > C (p.Asp40Ala), c.122_124delCCT (p.Ser41del), c.780_782delCAT (p.Iso260del) and c.957 + 1G > C). Treatment using 2,3 dimercaptosuccinic acid as a manganese chelating agent showed satisfactory results with improvement of biochemical markers, hepatic manifestations and relative amelioration of the neurological symptoms. Our findings present a large cohort of patients with HMDPC from same ethnic group. The majority of our patients showed severe and early presentation with clear phenotypic variability among sibship. Moreover, we extend the phenotypic and mutational spectrum and emphasize the importance of early diagnosis and treatment of this potentially fatal disorder. We describe 10 patients with hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis syndrome carrying 6 novel homozygous SLC30A10 mutations. Our patients had a striking early onset of symptoms (
doi_str_mv 10.1111/cge.13184
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1971655271</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2013610730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3534-d9b40a9975f9a1486ebf4083751e21d257d86791943ac9a2762ed2d31be0182a3</originalsourceid><addsrcrecordid>eNp1kc1q3DAUhUVIaSbTLvICRZBNA3GiK_lP2YUhP4WBLtKuhca6zijYkivZTf0KfeqoM0kXhWpzEefTubr3EHIC7ALSuWwe8QIE1PkBWYCQMmOM5YdkkYrMJJTiiBzH-JSuoirke3LEJUjBRL4gv-_nAUOv3aN2GLG3mj7bcUvNHEfvrD6ng-_mZh63O007QxsbwtZHG6l1FBgd9GjRjfGKPthf1Pmf2NGH9Uqw6yT205hk7-LuaTuFZBTosEXnx9SZGuyswx3ygbxrdRfx42tdku-3N99W99n6692X1fU6a0Qh8szITc60lFXRSg15XeKmzVmdJgPkYHhRmbqs0oC50I3UvCo5Gm4EbJBBzbVYks973yH4HxPGUfU2Nth1aQN-igpkBWVR8AoSevoP-uSn4NLvFGcgSmBVWuOSnO2pJvgYA7ZqCLbXYVbA1J-AVApI7QJK7KdXx2nTo_lLviWSgMs98Gw7nP_vpFZ3N3vLF5XumbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2013610730</pqid></control><display><type>article</type><title>Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation</title><source>Access via Wiley Online Library</source><creator>Zaki, M.S. ; Issa, M.Y. ; Elbendary, H.M. ; El‐Karaksy, H. ; Hosny, H. ; Ghobrial, C. ; El Safty, A. ; El‐Hennawy, A. ; Oraby, A. ; Selim, L. ; Abdel‐Hamid, M.S.</creator><creatorcontrib>Zaki, M.S. ; Issa, M.Y. ; Elbendary, H.M. ; El‐Karaksy, H. ; Hosny, H. ; Ghobrial, C. ; El Safty, A. ; El‐Hennawy, A. ; Oraby, A. ; Selim, L. ; Abdel‐Hamid, M.S.</creatorcontrib><description>Biallelic mutations in the SLC30A10 gene cause an inborn error of Mn metabolism characterized by hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis (HMDPC). To date, only 14 families from various ethnic groups have been reported. Here, we describe 10 patients from 7 unrelated Egyptian families with HMDPC. Markedly elevated blood Mn levels, the characteristic basal ganglia hyperintensity on T1‐weighted images, and variable degrees of extrapyramidal manifestations with or without liver disease were cardinal features in all patients. Eight patients presented with striking early diseased onset (≤2 years). Unexpectedly, early hepatic involvement before the neurological regression was noted in 3 patients. Mutational analysis of SLC30A10 gene revealed 6 novel homozygous mutations (c.77T &gt; C (p.Leu26Pro), c.90C &gt; G (p.Tyr30*), c.119A &gt; C (p.Asp40Ala), c.122_124delCCT (p.Ser41del), c.780_782delCAT (p.Iso260del) and c.957 + 1G &gt; C). Treatment using 2,3 dimercaptosuccinic acid as a manganese chelating agent showed satisfactory results with improvement of biochemical markers, hepatic manifestations and relative amelioration of the neurological symptoms. Our findings present a large cohort of patients with HMDPC from same ethnic group. The majority of our patients showed severe and early presentation with clear phenotypic variability among sibship. Moreover, we extend the phenotypic and mutational spectrum and emphasize the importance of early diagnosis and treatment of this potentially fatal disorder. We describe 10 patients with hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis syndrome carrying 6 novel homozygous SLC30A10 mutations. Our patients had a striking early onset of symptoms (&lt;2 years) with unexpected early hepatic involvement before the neurological regression in some patients. Treatment with 2,3 dimercaptosuccinic acid showed satisfactory results and improvement of biochemical markets, hepatic manifestations and relative amelioration of the neurological symptoms. Thus, we believe that we expanded the mutational spectrum and further delineate the phenotypic spectrum of this very rare inborn error of Mn metabolism.</description><identifier>ISSN: 0009-9163</identifier><identifier>EISSN: 1399-0004</identifier><identifier>DOI: 10.1111/cge.13184</identifier><identifier>PMID: 29193034</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Basal ganglia ; Biochemical markers ; Cirrhosis ; DMSA ; Dystonia ; early phenotype ; Genetic variability ; Liver cirrhosis ; Liver diseases ; Manganese ; Minority &amp; ethnic groups ; Mutation ; Phenotypes ; Polycythemia ; SLC30A10</subject><ispartof>Clinical genetics, 2018-04, Vol.93 (4), p.905-912</ispartof><rights>2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</rights><rights>2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</rights><rights>2018 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3534-d9b40a9975f9a1486ebf4083751e21d257d86791943ac9a2762ed2d31be0182a3</citedby><cites>FETCH-LOGICAL-c3534-d9b40a9975f9a1486ebf4083751e21d257d86791943ac9a2762ed2d31be0182a3</cites><orcidid>0000-0001-7840-0002</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcge.13184$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcge.13184$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29193034$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zaki, M.S.</creatorcontrib><creatorcontrib>Issa, M.Y.</creatorcontrib><creatorcontrib>Elbendary, H.M.</creatorcontrib><creatorcontrib>El‐Karaksy, H.</creatorcontrib><creatorcontrib>Hosny, H.</creatorcontrib><creatorcontrib>Ghobrial, C.</creatorcontrib><creatorcontrib>El Safty, A.</creatorcontrib><creatorcontrib>El‐Hennawy, A.</creatorcontrib><creatorcontrib>Oraby, A.</creatorcontrib><creatorcontrib>Selim, L.</creatorcontrib><creatorcontrib>Abdel‐Hamid, M.S.</creatorcontrib><title>Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation</title><title>Clinical genetics</title><addtitle>Clin Genet</addtitle><description>Biallelic mutations in the SLC30A10 gene cause an inborn error of Mn metabolism characterized by hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis (HMDPC). To date, only 14 families from various ethnic groups have been reported. Here, we describe 10 patients from 7 unrelated Egyptian families with HMDPC. Markedly elevated blood Mn levels, the characteristic basal ganglia hyperintensity on T1‐weighted images, and variable degrees of extrapyramidal manifestations with or without liver disease were cardinal features in all patients. Eight patients presented with striking early diseased onset (≤2 years). Unexpectedly, early hepatic involvement before the neurological regression was noted in 3 patients. Mutational analysis of SLC30A10 gene revealed 6 novel homozygous mutations (c.77T &gt; C (p.Leu26Pro), c.90C &gt; G (p.Tyr30*), c.119A &gt; C (p.Asp40Ala), c.122_124delCCT (p.Ser41del), c.780_782delCAT (p.Iso260del) and c.957 + 1G &gt; C). Treatment using 2,3 dimercaptosuccinic acid as a manganese chelating agent showed satisfactory results with improvement of biochemical markers, hepatic manifestations and relative amelioration of the neurological symptoms. Our findings present a large cohort of patients with HMDPC from same ethnic group. The majority of our patients showed severe and early presentation with clear phenotypic variability among sibship. Moreover, we extend the phenotypic and mutational spectrum and emphasize the importance of early diagnosis and treatment of this potentially fatal disorder. We describe 10 patients with hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis syndrome carrying 6 novel homozygous SLC30A10 mutations. Our patients had a striking early onset of symptoms (&lt;2 years) with unexpected early hepatic involvement before the neurological regression in some patients. Treatment with 2,3 dimercaptosuccinic acid showed satisfactory results and improvement of biochemical markets, hepatic manifestations and relative amelioration of the neurological symptoms. Thus, we believe that we expanded the mutational spectrum and further delineate the phenotypic spectrum of this very rare inborn error of Mn metabolism.</description><subject>Basal ganglia</subject><subject>Biochemical markers</subject><subject>Cirrhosis</subject><subject>DMSA</subject><subject>Dystonia</subject><subject>early phenotype</subject><subject>Genetic variability</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Manganese</subject><subject>Minority &amp; ethnic groups</subject><subject>Mutation</subject><subject>Phenotypes</subject><subject>Polycythemia</subject><subject>SLC30A10</subject><issn>0009-9163</issn><issn>1399-0004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kc1q3DAUhUVIaSbTLvICRZBNA3GiK_lP2YUhP4WBLtKuhca6zijYkivZTf0KfeqoM0kXhWpzEefTubr3EHIC7ALSuWwe8QIE1PkBWYCQMmOM5YdkkYrMJJTiiBzH-JSuoirke3LEJUjBRL4gv-_nAUOv3aN2GLG3mj7bcUvNHEfvrD6ng-_mZh63O007QxsbwtZHG6l1FBgd9GjRjfGKPthf1Pmf2NGH9Uqw6yT205hk7-LuaTuFZBTosEXnx9SZGuyswx3ygbxrdRfx42tdku-3N99W99n6692X1fU6a0Qh8szITc60lFXRSg15XeKmzVmdJgPkYHhRmbqs0oC50I3UvCo5Gm4EbJBBzbVYks973yH4HxPGUfU2Nth1aQN-igpkBWVR8AoSevoP-uSn4NLvFGcgSmBVWuOSnO2pJvgYA7ZqCLbXYVbA1J-AVApI7QJK7KdXx2nTo_lLviWSgMs98Gw7nP_vpFZ3N3vLF5XumbA</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Zaki, M.S.</creator><creator>Issa, M.Y.</creator><creator>Elbendary, H.M.</creator><creator>El‐Karaksy, H.</creator><creator>Hosny, H.</creator><creator>Ghobrial, C.</creator><creator>El Safty, A.</creator><creator>El‐Hennawy, A.</creator><creator>Oraby, A.</creator><creator>Selim, L.</creator><creator>Abdel‐Hamid, M.S.</creator><general>Blackwell Publishing Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7840-0002</orcidid></search><sort><creationdate>201804</creationdate><title>Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation</title><author>Zaki, M.S. ; Issa, M.Y. ; Elbendary, H.M. ; El‐Karaksy, H. ; Hosny, H. ; Ghobrial, C. ; El Safty, A. ; El‐Hennawy, A. ; Oraby, A. ; Selim, L. ; Abdel‐Hamid, M.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3534-d9b40a9975f9a1486ebf4083751e21d257d86791943ac9a2762ed2d31be0182a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Basal ganglia</topic><topic>Biochemical markers</topic><topic>Cirrhosis</topic><topic>DMSA</topic><topic>Dystonia</topic><topic>early phenotype</topic><topic>Genetic variability</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Manganese</topic><topic>Minority &amp; ethnic groups</topic><topic>Mutation</topic><topic>Phenotypes</topic><topic>Polycythemia</topic><topic>SLC30A10</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zaki, M.S.</creatorcontrib><creatorcontrib>Issa, M.Y.</creatorcontrib><creatorcontrib>Elbendary, H.M.</creatorcontrib><creatorcontrib>El‐Karaksy, H.</creatorcontrib><creatorcontrib>Hosny, H.</creatorcontrib><creatorcontrib>Ghobrial, C.</creatorcontrib><creatorcontrib>El Safty, A.</creatorcontrib><creatorcontrib>El‐Hennawy, A.</creatorcontrib><creatorcontrib>Oraby, A.</creatorcontrib><creatorcontrib>Selim, L.</creatorcontrib><creatorcontrib>Abdel‐Hamid, M.S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zaki, M.S.</au><au>Issa, M.Y.</au><au>Elbendary, H.M.</au><au>El‐Karaksy, H.</au><au>Hosny, H.</au><au>Ghobrial, C.</au><au>El Safty, A.</au><au>El‐Hennawy, A.</au><au>Oraby, A.</au><au>Selim, L.</au><au>Abdel‐Hamid, M.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation</atitle><jtitle>Clinical genetics</jtitle><addtitle>Clin Genet</addtitle><date>2018-04</date><risdate>2018</risdate><volume>93</volume><issue>4</issue><spage>905</spage><epage>912</epage><pages>905-912</pages><issn>0009-9163</issn><eissn>1399-0004</eissn><abstract>Biallelic mutations in the SLC30A10 gene cause an inborn error of Mn metabolism characterized by hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis (HMDPC). To date, only 14 families from various ethnic groups have been reported. Here, we describe 10 patients from 7 unrelated Egyptian families with HMDPC. Markedly elevated blood Mn levels, the characteristic basal ganglia hyperintensity on T1‐weighted images, and variable degrees of extrapyramidal manifestations with or without liver disease were cardinal features in all patients. Eight patients presented with striking early diseased onset (≤2 years). Unexpectedly, early hepatic involvement before the neurological regression was noted in 3 patients. Mutational analysis of SLC30A10 gene revealed 6 novel homozygous mutations (c.77T &gt; C (p.Leu26Pro), c.90C &gt; G (p.Tyr30*), c.119A &gt; C (p.Asp40Ala), c.122_124delCCT (p.Ser41del), c.780_782delCAT (p.Iso260del) and c.957 + 1G &gt; C). Treatment using 2,3 dimercaptosuccinic acid as a manganese chelating agent showed satisfactory results with improvement of biochemical markers, hepatic manifestations and relative amelioration of the neurological symptoms. Our findings present a large cohort of patients with HMDPC from same ethnic group. The majority of our patients showed severe and early presentation with clear phenotypic variability among sibship. Moreover, we extend the phenotypic and mutational spectrum and emphasize the importance of early diagnosis and treatment of this potentially fatal disorder. We describe 10 patients with hypermanganesemia, polycythemia, early‐onset dystonia, and liver cirrhosis syndrome carrying 6 novel homozygous SLC30A10 mutations. Our patients had a striking early onset of symptoms (&lt;2 years) with unexpected early hepatic involvement before the neurological regression in some patients. Treatment with 2,3 dimercaptosuccinic acid showed satisfactory results and improvement of biochemical markets, hepatic manifestations and relative amelioration of the neurological symptoms. Thus, we believe that we expanded the mutational spectrum and further delineate the phenotypic spectrum of this very rare inborn error of Mn metabolism.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>29193034</pmid><doi>10.1111/cge.13184</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7840-0002</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0009-9163
ispartof Clinical genetics, 2018-04, Vol.93 (4), p.905-912
issn 0009-9163
1399-0004
language eng
recordid cdi_proquest_miscellaneous_1971655271
source Access via Wiley Online Library
subjects Basal ganglia
Biochemical markers
Cirrhosis
DMSA
Dystonia
early phenotype
Genetic variability
Liver cirrhosis
Liver diseases
Manganese
Minority & ethnic groups
Mutation
Phenotypes
Polycythemia
SLC30A10
title Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A16%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypermanganesemia%20with%20dystonia,%20polycythemia%20and%20cirrhosis%20in%2010%20patients:%20Six%20novel%20SLC30A10%20mutations%20and%20further%20phenotype%20delineation&rft.jtitle=Clinical%20genetics&rft.au=Zaki,%20M.S.&rft.date=2018-04&rft.volume=93&rft.issue=4&rft.spage=905&rft.epage=912&rft.pages=905-912&rft.issn=0009-9163&rft.eissn=1399-0004&rft_id=info:doi/10.1111/cge.13184&rft_dat=%3Cproquest_cross%3E2013610730%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2013610730&rft_id=info:pmid/29193034&rfr_iscdi=true